Published Online: Saturday, September 1, 2007

The appetite for generic drugs throughout the European Community is expected to double in the next 7 years, jumping from $17.18 billion in 2006 to nearly $36 billion by 2013, according to a new market analysis by Frost & Sullivan. As in the United States, rising health costs in Europe are causing government leaders to explore methods for promoting increased use of more cost-effective generic medicines, the study noted.

?Patent expiries, pro-generic reforms in certain countries, and need for cheap, effective medicines are the key factors driving growth in the European generics market,? a researcher for the company explained. ?Various studies have indicated the cost savings obtained from generics, and several governments in Europe are actively promoting generics.?

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues